IL33 and neoplasm: Overall, these studies suggest that despite the divergent effects of ILC2 in tumor immunity, proper activation, such as with IL-33/ST2 stimulation, may promote the anti-tumor functions of these cells through multiple mechanisms, including recruitment of eosinophils and cross-presenting DCs, and tumor cytotoxicity.